Overview

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Status:
Completed
Trial end date:
2019-10-07
Target enrollment:
Participant gender:
Summary
This study is a phase 1, double-blind, placebo-controlled, multiple ascending dose study to determine the safety, tolerability, and pharmacokinetics of SAGE-718 oral solution in healthy adults (Part A) with an open-label cohort of patients with Huntington's disease (Part B)
Phase:
Phase 1
Details
Lead Sponsor:
Sage Therapeutics